Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candi-date Malaria Vaccine (SB257049) Evaluating Schedules With or With-out Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs GSK 257049 (Primary) ; Rabies vaccine
- Indications Falciparum malaria
- Focus Proof of concept; Therapeutic Use
- Acronyms MALARIA-094
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
- 24 May 2019 Planned primary completion date changed from 19 Jun 2020 to 16 Jul 2020.
- 02 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Jun 2018 Planned End Date changed from 25 Nov 2022 to 15 Dec 2022.